In this issue:
Inebilizumab for generalised myasthenia gravis
ICIs for pre-existing autoimmune neurologic disorders
Long-term effectiveness and safety of rituximab in NMOSD
Ofatumumab for anti-NMDAR autoimmune encephalitis
Treatment patterns and disease burden of juvenile myasthenia gravis
Nicotine, alcohol, and myasthenia gravis risk
Rituximab in anti-NMDAR antibody-mediated encephalitis
Commercial tissue-based assays for intracellular antigens
Commercial tissue-based assays for surface antigens
Immune-treatment in anti‑LGI1antibody-mediated encephalitis
Please login below to download this issue (PDF)